2022 World Conference on Lung Cancer (ePosters)-EP08.02-139. A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

EP08.02-139. A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

Pdf Summary

The document summarizes a clinical study on the drug D-0316 (befotertinib) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with T790M mutation. The study enrolled a total of 466 patients in different dose cohorts and evaluated the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).<br /><br />The results showed that the higher dose cohort (75-100mg) had higher ORR and DCR compared to the lower dose cohort (50mg). The median PFS was also longer in the higher dose cohort.<br /><br />The document also mentions the treatment-related adverse events (AEs) experienced by the patients, including diarrhea, rash/acne, and paronychia, which were mostly mild or moderate. No treatment-related deaths were reported.<br /><br />Overall, the study suggests that D-0316 has the potential as a treatment option for patients with NSCLC with T790M mutation who have resistance to first- or second-generation EGFR TKIs. However, further studies are needed to confirm these findings and provide more evidence on the long-term outcomes of D-0316 treatment. The study was sponsored by Betta Pharmaceuticals Co., Ltd., who contributed to the data analysis, study monitoring, and medical-writing support.

Asset Subtitle

Shun Lu

Meta Tag

Speaker Shun Lu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

D-0316

befotertinib

clinical study

non-small cell lung cancer

NSCLC

T790M mutation

objective response rate

disease control rate

progression-free survival

adverse events